Chronic myeloid leukemia: First-line drug of choice

American Journal of Hematology
Elias Jabbour

Abstract

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has been considered the standard of care for more than a decade. Second generation compounds, namely dasatinib and nilotinib, are highly effective in newly diagnosed patients as well as those who fail imatinib. Second generation TKIs have been demonstrated to induce deeper and faster responses compared to imatinib, however no survival advantage has been observed so far. Today, the expected survival of CML patients, if properly managed, is likely to be similar to the general population. Clinicians are faced the challenge of making decision for which TKI to choose upfront. Comorbidities of the patient, the side effect profile, and the cost of the TKI of interest should be an important consideration in decision making. Whatever TKI is chosen as frontline, noncompliance or treatment failure should be recognized early as a prompt intervention increases the chance of achieving best possible response. Herein, we review the frontline options for the management of patients with CML and how to best choose these agents.

References

Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·A B RaitanoC L Sawyers
Mar 1, 2002·The New England Journal of Medicine·Hagop KantarjianUNKNOWN International STI571 CML Study Group
Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
May 25, 2006·British Journal of Cancer·E WeisbergJ D Griffin
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Jun 16, 2006·The New England Journal of Medicine·Hagop KantarjianOliver G Ottmann
Jun 16, 2006·The New England Journal of Medicine·Brian J Druker
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaJorge Cortes
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil P ShahAndreas Hochhaus
Jun 3, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianJorge Cortes
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesUNKNOWN Rationale and Insight for Gleevec High-Dose Therapy (RIGHT) Trial Study Group
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele BaccaraniUNKNOWN European LeukemiaNet
Apr 28, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Deborah L WhiteTimothy P Hughes
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Dec 24, 2010·The New England Journal of Medicine·Claude PreudhommeUNKNOWN France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC)
Mar 23, 2011·Journal of the National Cancer Institute·Carlo Gambacorti-PasseriniDong-Wook Kim
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop Kantarjian, Jorge Cortes
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rüdiger HehlmannSusanne Saussele
May 4, 2011·American Journal of Hematology·Karl J AichbergerPeter Valent
May 27, 2011·The New England Journal of Medicine·Thomas J Smith, Bruce E Hillner
Oct 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elias JabbourJorge E Cortes
Nov 10, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinLetizia Foroni
May 29, 2012·Clinical Lymphoma, Myeloma & Leukemia·Alfonso Quintás-CardamaJorge Cortes
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini

❮ Previous
Next ❯

Citations

Jul 5, 2016·Frontiers in Cell and Developmental Biology·Roser BuscàPhilippe Lenormand
Oct 21, 2016·Expert Opinion on Therapeutic Patents·Joohun Ha, Joungmok Kim
Jul 19, 2016·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Eric Hesse
Mar 23, 2017·Expert Review of Anti-infective Therapy·Juan AmbrosioniJosé M Miró
Aug 15, 2019·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Jessica PottsMamas A Mamas
Apr 3, 2020·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Feb 8, 2018·American Journal of Hematology·Elias Jabbour, Hagop Kantarjian
Mar 13, 2018·Physiological Research·V VenturiM Pospisek
Sep 30, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jeffrey R AndolinaMichael E Roth
May 19, 2021·Leukemia·Michele Baccarani, Robert Peter Gale
Jun 3, 2021·Expert Review of Hematology·Massimo BrecciaMaurizio Martelli

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.